Bevacizumab
- PDF / 139,887 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 49 Downloads / 147 Views
1
S
Various toxicities: 3 case reports A retrospective study identified three patients who developed a toxicity during treatment with bevacizumab for active central nervous system (CNS) metastases from nonsmall cell lung cancer [dosage, route, time to reaction onset and patient outcomes not stated]. The first patient, a 77-yearold man developed chronic skin ulceration at the site of a pilonidal cyst; bevacizumab was withdrawn due to toxicity. The second patient, a woman, aged 59 years, developed pulmonary embolus. The third patient, a 60-year-old woman developed an asymptomatic (Grade 1) CNS haemorrhage; she was receiving concomitant anticoagulants. Author comment: "Bevacizumab should be used with caution in patients with active CNS metastases pending additional safety data." De Braganca KC, et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology 100: 443-447, No. 3, Dec 2010. Available from: URL: http://dx.doi.org/10.1007/ 803047589 s11060-010-0200-2 - USA
0114-9954/10/1334-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 15 Jan 2011 No. 1334
Data Loading...
